Moringa Oleifera and Phoenix Dactylifera L. Effects on Cortisol and Breast Milk in Postpartum Depression

NCT07337512 | Completed DMC

• 2 other identifiers: DP.04.03/F.XXXVI.15/010/20247011.PKPT.001.43321
• Study Type: interventional
• Target: 363
• Locations: 1 country
• Sites: 1

Brief Summary

Postpartum depression affects 10-20% of new mothers globally, potentially disrupting breast milk production. This study aimed to provide valuable insights into effective interventions to improve the health and well-being of Postpartum Mothers with depression. This study used a randomized controlled trial design with three groups: intervention 1 (dates), intervention 2 (Moringa oleifera), and a control group. A total of 363 postpartum mothers participated, and data were collected through salivary cortisol levels (ELISA) and Beck Depression Inventory (BDI) scores to measure depression levels and breast milk production (ACIS AC-15X digital scale and Crown electric breast pump) before and after the intervention for 28 days. Data analysis was performed using paired sample t-test and the independent t-test.

Conditions

Postpartum Depression (PPD)

Keywords

Moringa oleifera Leaf; Phoenix dactylifera L; Salivary Cortisol; Breast Milk; Postpartum Mother; Depression

Outcome Measures

Primary Outcomes (1)

• Changes in Depression Levels of Breastfeeding Mothers (Based on BDI Scores), cortisol levels and breast milk production in each group

  This study has more than one outcome measure with different units of measurement, so each variable should be expressed as a separate outcome measure and not combined unless a composite formula is defined. To clarify reporting, the Outcome Measures are revised as follows. Evaluation time points (for all outcomes): Week 0 (pre-intervention) and Week 4 (day 28 post-intervention). Primary/secondary outcomes (reported separately): 1. Depression: Beck Depression Inventory (BDI) score, interval scale (unit: BDI score), measured at Week 0 and Week 4. 2. Salivary cortisol level: Salivary cortisol concentration (unit: μg/dL), measured at Week 0 and Week 4. 3. Breast milk production: Breast milk volume (unit: mL), measured at Week 0 and Week 4.

  before the intervention and after 28 days of intervention. Assessments took place in week 1 (week 0) and week 4 (after 28 days).

Study Arms (1)

3

ACTIVE COMPARATOR

This study employed a three-arm design over 28 days comparing two active interventions against placebo control. The Phoenix dactylifera L. group received 120g daily dates (40g portions thrice daily) using food-grade certified products with precise digital scaling (±0.1g accuracy) and controlled storage in airtight containers with humidity regulation. The Moringa oleifera group received pharmaceutical-grade capsules at 1000mg daily (500mg twice daily) with analytical balance verification (±0.1mg) and amber glass storage for light protection. The placebo group maintained regular three-daily meals without additional intervention. Both active groups utilized standardized measurement protocols, quality-certified materials, and comprehensive documentation systems including food diaries and visual monitoring to ensure intervention fidelity and participant compliance throughout the study period.

Drug: Phoenix dactylifera L; Drug: Moringa oleifera; Other: Placebo: consumed food three times a day

Interventions

Phoenix dactylifera L DRUG

The intervention method in this study used Phoenix dactylifera L. (dates) as the main ingredient with a standardized dose of 120 grams per day per participant, divided into three 40-gram portions over a 28-day period. The dates used were food-grade with a Certificate of Analysis (CoA) certification from a trusted supplier to ensure quality and safety of consumption. Measurement instrumentation included a digital scale with an accuracy of ±0.1 grams for daily portions, an analytical balance for high-precision measurements, and a measuring cup to ensure portion consistency. The storage and distribution system was designed using food-grade airtight containers, individual plastic bags, a cooler box for transportation, and silica gel packets for humidity control, equipped with a waterproof labeling system. Documentation and monitoring were carried out using a food diary form, a 28-day intervention calendar, and a digital camera for visual documentation.

3

Moringa oleifera DRUG

Moringa oleifera: The intervention method in this study used Moringa oleifera capsules as the primary therapeutic agent at a standard dose of 1000 mg per day per participant, administered in two divided doses of 500 mg each (morning and evening) for a 28-day period. The Moringa oleifera capsules used were pharmaceutical-grade capsules with appropriate quality certification from a verified supplier to ensure purity and safety for human consumption. Measurement instruments included a precision analytical balance with an accuracy of ±0.1 mg for capsule weight verification, an automatic capsule counter for dose consistency, and a calibrated measuring device to ensure uniform distribution. The storage and distribution system was implemented using pharmaceutical-grade amber glass containers to protect from light degradation, individual blister packs for daily doses, temperature-controlled storage units, and desiccant packs for humidity control, equipped with a labeling system that indicated

3

Placebo: consumed food three times a day OTHER

consumed food three times a day: Participants received no additional intervention and only consumed food three times a day for 28 days, serving as a baseline to compare the effects of the intervention.

3

Eligibility Criteria

• Age: 18 Years - 35 Years
• Gender Eligibility Details: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Individuals aged 18-35 years
• Mothers with infants aged 2 weeks to 6 months
• Body Mass Index (BMI) greater than 18.7
• Scores on the Beck Depression Inventory (BDI) ranging from mild to severe depression
• Breast milk production of less than 300 g/day

You may not qualify if:

• Mothers with endocrine disorders
• Acute or chronic diseases
• Conditions such as hypoplastic breast tissue
• Use of combined estrogen contraceptives
• Mothers who smoke or consume alcohol

Sponsors & Collaborators

• Indonesia-MoH: collaborator
• Melania Asi: lead

Study Sites (1)

Poltekkes Kemenkes Kendari

Kendari, Southeast Sulawesi, 93231, Indonesia

Location

MeSH Terms

Conditions

Depression, Postpartum; Depression

Interventions

flocculant protein MO 2.1, Moringa oleifera

Condition Hierarchy (Ancestors)

Puerperal Disorders; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Depressive Disorder; Mood Disorders; Mental Disorders; Behavioral Symptoms; Behavior

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Director

Study Record Dates

• First Submitted: December 6, 2025
• First Posted: January 13, 2026
• Study Start: May 19, 2024
• Primary Completion: November 19, 2024
• Study Completion: November 19, 2024
• Last Updated: January 13, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

ID (1)